Why is Zerbaxa (ceftolozane/tazobactam) infused over one hour for patients with normal renal function and over three hours for patients with impaired renal function?

Zerbaxa Infusion Duration: Standard 1-Hour vs. Extended 3-Hour Infusion

Zerbaxa (ceftolozane/tazobactam) is standardly infused over 1 hour for all patients regardless of renal function—there is no routine 3-hour infusion recommendation in the FDA-approved labeling. The confusion may arise from general beta-lactam optimization strategies or specific clinical scenarios, but the approved dosing specifies 1-hour infusions across all renal function categories 1.

FDA-Approved Infusion Duration

The FDA label is explicit and consistent:

• All standard doses: 1-hour intravenous infusion 1
• Normal renal function (CrCl >50 mL/min): 1.5g or 3g every 8 hours over 1 hour
• Renal impairment (CrCl 15-50 mL/min): Reduced doses, still over 1 hour
• End-stage renal disease on hemodialysis: Loading dose followed by maintenance doses, all over 1 hour 1

The infusion time does NOT change to 3 hours based on renal function in the approved labeling.

When Extended Infusions May Be Considered

While not FDA-mandated for Zerbaxa specifically, extended infusions (3 hours) of beta-lactams are discussed in critical care guidelines for pharmacokinetic/pharmacodynamic optimization 2:

Rationale for Extended Infusions:

• Beta-lactam PK/PD principle: Time-dependent killing—efficacy correlates with the percentage of time free drug concentration exceeds the MIC (fT>MIC) 3
• Target optimization: Achieving 100% fT>MIC (rather than just 40-60%) may improve outcomes in severe infections, particularly with resistant organisms or high MICs 2
• Critical illness factors: Augmented renal clearance, increased volume of distribution, and altered pharmacokinetics in septic patients can reduce drug concentrations 3, 4

Clinical Scenarios Where Extended Infusion Might Be Used:

• Augmented renal clearance (CrCl ≥130 mL/min): Standard dosing may result in suboptimal trough levels 4
• High MIC organisms: When treating Pseudomonas aeruginosa with MICs approaching breakpoints (4-8 µg/mL) 5
• Critically ill patients: Septic shock, HABP/VABP with hemodynamic instability 2

However, these are off-label optimization strategies, not standard practice per FDA labeling.

Pharmacokinetic Evidence

Research demonstrates:

• 1-hour infusion: Achieves >90% probability of target attainment (PTA) for bactericidal activity (32.2% fT>MIC) at MICs up to 4 µg/mL in normal renal function 6
• Renal impairment: Actually improves PTA due to reduced clearance—93% achieve bactericidal targets at MICs up to 8 µg/mL with dose-adjusted 1-hour infusions 6, 7
• Extended infusions: Monte Carlo simulations show 3-hour infusions increase fT>100%MIC from 82% to 86% with 1g doses in augmented renal clearance, but 2g doses achieve >90% even with 1-hour infusions 5

Practical Dosing Algorithm

For standard practice, follow FDA labeling:

1. Normal renal function (CrCl >50 mL/min):

   • cIAI/cUTI: 1.5g every 8 hours over 1 hour
   • HABP/VABP: 3g every 8 hours over 1 hour 1

2. Moderate renal impairment (CrCl 30-50 mL/min):

   • Reduce dose, maintain 1-hour infusion 1

3. Severe renal impairment/ESRD:

   • Further dose reduction, still 1-hour infusion 1, 8

For off-label optimization in specific scenarios (requires infectious disease consultation):

• Augmented renal clearance + high MIC: Consider 3g dose with 3-hour infusion 5
• Critically ill with septic shock: Extended infusion may be considered as part of beta-lactam optimization strategy 2
• Therapeutic drug monitoring available: Adjust based on measured levels

Common Pitfalls

• Assuming renal impairment requires longer infusion: The opposite is true—reduced clearance improves drug exposure, requiring dose reduction but not infusion prolongation 7
• Confusing with other beta-lactams: Piperacillin/tazobactam and meropenem have more robust data supporting extended infusions; extrapolating this to Zerbaxa is not evidence-based for routine use 2
• Overlooking dose adjustment: Renal function changes require dose modification, not infusion time changes 1

The standard of care remains 1-hour infusions per FDA labeling, with extended infusions reserved for specific optimization scenarios in consultation with infectious disease specialists.